KRAS and neoplasm: In the mouse model of PDAC, SMO-independent GLI1 activation promotes transformation and requires both TGFβ and KRAS signaling (84) where inhibition of TGFβ by TbRI antagonist SD208 significantly reduces tumor burden and increases infiltration of lymphocytes.